JETRO-Ensanté BioTech Networking Event

Join us on November 22nd at the JIC (Japan Innovation Campus) in Palo Alto for an inspiring afternoon focused on groundbreaking innovations across biotech and life sciences — all brought to you by 5 top biotech startups from Japan. This is a unique opportunity to witness firsthand the cutting-edge innovations coming out of Japan’s entrepreneurial ecosystem.
Enjoy a catered lunch while networking to connect with fellow investors, entrepreneurs, and professionals passionate about biotech innovation. Build relationships, explore collaboration opportunities, and engage with like-minded individuals working to drive the future of biotech and life sciences. A variety of appetizers and beverages will be served to keep the conversations flowing.
Our 5 Featured Startups:
iBody has a patent-protected monoclonal antibody discovery platform technology. It enabled us to conduct the exhaustive and fastest (2 days) monoclonal antibody discovery in the world. We have commercial success in monoclonal antibody discovery for pharmaceutical and diagnostic drug companies in Japan. These monoclonal antibodies have been applied to drug discovery, diagnostic drug development, and research tools.

Physiologas Technologies, a Kitasato University startup, is pioneering a waterless home hemodialysis system that recycles dialysate within the device, removing the need for plumbing and easing physical and time demands on patients. After successful live animal testing with our proof of principal, we're currently fundraising to refine engineering and prepare for upcoming non-clinical trials.

PURMX provides a Cancer treatment such as against resistance/recurring cancers, and Poor QoL, which current anti-cancer drug cannot solve, leveraging microRNA technology. Our first product, MIRX002, is microRNA miR-3140-3p accelerates cancer cell aging. We are expanding indication from malignant plural mesothelioma to head and neck cancer, conducting global Phase 1/2 study as dual indication/dual route study and obtained acceptance from US FDA. Also, we are researching systemic formulation to expand further to various cancer types.

SCAD is developing regenerative medicine for damaged nerves. This will be the world's first cell therapy using proprietary stem cell-derived Schwann cells, from clinical grade ES cells. SCAD is the only company that can provide stable human-derived Schwann cells at large scale. Through collaborative research with Kyoto University, we have confirmed nerve regeneration in animal experiments on sciatic nerve crush injury models in rats. It can be applied to various types of nerve damage, e.g. spinal cord injury.

Fermelanta leverages synthetic biology to provide stable access to valuable plant-based molecules through advanced microbial fermentation. Traditional sourcing methods, such as agriculture and chemical synthesis, can be costly, unreliable, and unsustainable. Our scalable microbial cell-factories effectively address these challenges, making supply chains for active ingredients in pharmaceuticals, cosmetics, and supplements more resilient, affordable, and sustainable.
We hope to see you there!

Host or Publisher Gail Christine Gannon